Tirzepatide dosage: reported doses and schedule
A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
Also called: Mounjaro, Zepbound, LY3298176, LY-3298176, Tirz.
GLP-1 / GIP / glucagon agonists · Dual GIP and GLP-1 receptor agonist · Evidence: Approved drug.
Typical reported dose: 2.5 mg once a week to start, up to 15 mg
- First human study: single 0.25 mg: 0.25 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
- First human study: single 0.5 mg: 0.5 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
- First human study: single 1 mg: 1 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
- First human study: single 2.5 mg: 2.5 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
- First human study: single 5 mg: 5 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
- First human study: single 8 mg: 8 mg once single dose, under the skin. Studied in a trial. Studied in: Healthy adults. (source)
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to Tirzepatide
- Semaglutide: A GLP-1 medicine with strong weight, glucose, heart and kidney evidence; dose and formulation matter.
- Retatrutide: An experimental weekly injection with phase 3 weight-loss results.
- Liraglutide: A daily GLP-1 injection approved for weight management and type 2 diabetes.
- Dulaglutide: A weekly GLP-1 medicine approved for type 2 diabetes and lower heart-event risk.
- Exenatide: An older GLP-1 with twice-daily and weekly forms, now widely discontinued.
- Cagrilintide: An unapproved weekly amylin analogue with weight-loss trials and common stomach symptoms.
Sources
- FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, FDA · 2026
- FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List, FDA · 2026
- FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, FDA · 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, FDA · FDA · 2026
- The 2026 Monitoring Program, World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society., Mozaffarian D et al. · American journal of lifestyle medicine · 2025
- Update on the glucagon-like peptide-1 receptor agonists (GLP-1 RAs) pharmacy compounding changes, Therapeutic Goods Administration · 2024
- Assessment report: Mounjaro, European Medicines Agency
- DailyMed - MOUNJARO- tirzepatide injection, solution MOUNJARO KWIKPEN- tirzepatide injection, solution, DailyMed
- DailyMed - ZEPBOUND- tirzepatide injection, solution ZEPBOUND KWIKPEN- tirzepatide injection, solution, DailyMed
- GLP-1 medicines for weight loss and diabetes: what you need to know, MHRA · MHRA
- Mounjaro, European Medicines Agency
- MOUNJARO (Eli Lilly Australia Pty Ltd), Therapeutic Goods Administration
- Prescribing, reviewing and stopping tirzepatide, NICE
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.